Alnylam Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Amgen and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.7% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Amgen and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Amgen and Alnylam Pharmaceuticals, as reported by MarketBeat.

Amgen currently has a consensus target price of $254.08, indicating a potential upside of 15.33%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Amgen.

Summary

Amgen beats Alnylam Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Gilead Sciences has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Gilead Sciences and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Gilead Sciences and Alnylam Pharmaceuticals, as reported by MarketBeat.

Gilead Sciences currently has a consensus target price of $76.1538, indicating a potential upside of 27.99%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Gilead Sciences' higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Alnylam Pharmaceuticals.

Summary

Gilead Sciences beats Alnylam Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Vertex Pharmaceuticals and Alnylam Pharmaceuticals, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus target price of $290.5862, indicating a potential upside of 33.24%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Regeneron Pharmaceuticals has a consensus target price of $628.52, indicating a potential upside of 23.65%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Alnylam Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Biogen, as reported by MarketBeat.com.

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Biogen has a consensus target price of $305.9032, indicating a potential upside of 26.54%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.9% of Biogen shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biogen beats Alnylam Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Seagen, as reported by MarketBeat.com.

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Seagen has a consensus target price of $176.75, indicating a potential upside of 6.83%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Seagen.

Profitability

This table compares Alnylam Pharmaceuticals and Seagen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Seagen's top-line revenue, earnings per share and valuation.

Seagen has higher revenue and earnings than Alnylam Pharmaceuticals. Seagen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.0% of Seagen shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Seagen beats Alnylam Pharmaceuticals on 10 of the 15 factors compared between the two stocks.